The total process cost of parenteral antibiotic therapy: Beyond drug acquisition cost

Clinical Therapeutics

Volumn 18, Issue 4, 1996, Pages 716-725

  Hotchkies, Lorraine ^a   Grima, Daniel T ^a   Hedayati, Sam ^b  

^a Innovus Inc   (Canada)

^b Department of Medical Affairs   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANTIBIOTIC AGENT; CEFAZOLIN; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CLOXACILLIN; GENTAMICIN; TOBRAMYCIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CANADA; COST; DRUG COST; DRUG MONITORING; HOSPITAL INFECTION; HOSPITAL PHARMACY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PARENTERAL DRUG ADMINISTRATION; WASTE DISPOSAL;

EID: 0029764749     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(96)80222-0     Document Type: Article

References (18)

1. Misan GMH, Dollman C, Shaw DR, Burgess N. Cephalosporin utilisation review and evaluation. Pharmacoeconomics. 1995;8:100-122.
2. Davey P, Malek M. Pharmacoeconomics of antibacterial treatment. Curr Opin Infect Dis. 1990;3:782-785.
3. Barriere SL. Controversies in microbial therapy. Formulary decisions on third generation cephalosporins. Am J Hosp Pharm. 1986;43:625-629.
4. Col NF, O'Connor RW. Estimating worldwide current antibiotic usage: Report of Task Force One. Rev Infect Dis. 1987; 9(Suppl 3):S232-S243.
5. Unertl KE, Lenhart FP, Forst H, Peter K. Systemic antibiotic treatment of nosocomial pneumonia. Intensive Care Med. 1992;18(Suppl 1):S28-S34.
6. McClure CL. Common infections in the elderly. Am Fam Phys. 1992;45:2691-2698.
7. Davey PG, Vacani P, Parker SE, Malek MM. Assessing cost effectiveness of antimicrobial treatment: Monotherapy compared with combination therapy. Eur J Surg 1994;573:67-72.
8. Knothe H. Antibiotic usage for initial empirical treatment of infections in hospitalized patients in West Germany. Infection. 1991;19:127-130.
9. Brogan JC. Sorting out the cephalosporins. Postgrad Med. 1992;91:301-315.
10. Krogh CME. Compendium of Pharmaceuticals and Specialties - 1995. 30th ed. Ottawa, Canada: Canadian Pharmaceutical Association; 1995:1540-1542.
11. Noble JT, Barza M. Pharmacokinetic properties of the newer cephalosporins. A valid basis for drug selection? Drugs. 1985;30:175-181.
12. Davis R, Bryson HM. Ceftriaxone: A pharmacoeconomic evaluation of its use in the treatment of serious infections. Pharmacoeconomics. 1994;6:249-269.
13. Prince RA. Antimicrobial update. Drug Intell Clin Pharm. 1986;20:583-586.
14. Aoun M, Klastersky J. Drug treatment of pneumonia in the hospital. What are the choices? Drugs. 1991;42:962-973.
15. Conly JM, Gold W, Shafran SD. Once-daily aminoglycoside dosing: A new look at an old drug. Can J Infect Dis. 1994;5: 205-206.
16. Parker SE, Davey PG. Practicalities of once-daily aminoglycoside dosing. J Antimicrob Chemother. 1993;31:4-8.
17. Ontario Ministry of Health. Drug Benefit Formulary No. 34, Comparative Drug Index. Toronto, Ontario, Canada: Publications Ontario; 1994.
18. PPS. (Published price list, July 1.) Moncton, New Brunswick, Canada: Total Pricing Systems Inc; 1994.